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Mutation accumulation during life can contribute to
hematopoietic dysfunction; however, the underlying
dynamics are unknown. Somatic mutations in blood
progenitors can provide insight into the rate and pro-
cesses underlying this accumulation, as well as the
developmental lineage tree and stem cell division
numbers. Here, we catalogmutations in the genomes
of human-bone-marrow-derived and umbilical-cord-
blood-derived hematopoietic stem and progenitor
cells (HSPCs). We find that mutations accumulate
gradually during life with approximately 14 base sub-
stitutions per year. The majority of mutations were
acquired after birth and could be explained by the
constant activity of various endogenous mutagenic
processes, which also explains the mutation load in
acute myeloid leukemia (AML). Using these muta-
tions, we construct a developmental lineage tree of
human hematopoiesis, revealing a polyclonal archi-
tecture and providing evidence that developmental
clones exhibit multipotency. Our approach highlights
features of human native hematopoiesis and its
implications for leukemogenesis.
INTRODUCTION
Mature blood and immune cells are produced by the process of
hematopoiesis, which is orchestrated by self-renewing hemato-
poietic stem and progenitor cells (HSPCs) in the bone marrow.
As people age, clonal expansions of mutated stem cells within
the blood more commonly occur, which is associated with
increased risk of developing hematological malignancies (Geno-
vese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014). Somatic
mutations are thought to gradually accumulate in the genomes
of stem cells during life (Blokzijl et al., 2016). Most of these
mutations will not have any functional consequences; however,
some may render cells independent of specific external growth
factors or provide insensitivity to intrinsic inhibitory signals,2308 Cell Reports 25, 2308–2316, November 27, 2018 ª 2018 The A
This is an open access article under the CC BY-NC-ND license (http://thereby promoting uncontrolled clonal expansion (Stratton
et al., 2009). Although mutagenesis in HSPCs promotes
dysfunctional hematopoiesis and leukemia (Rossi et al., 2008;
Welch et al., 2012), the dynamics and mechanisms underlying
mutation accumulation in these cells in human bone marrow
are currently not well understood. In addition, clonal hematopoi-
esis is commonly observed in elderly and associated with an
increased risk of hematologic cancers and death (Genovese
et al., 2014; Jaiswal et al., 2014; Xie et al., 2014; Zink et al.,
2017); however, the clonal composition of hematopoietic tissue
within the normal human bone marrow has not been systemati-
cally determined.
Here, we assessed lifelong mutation accumulation in long-
term engrafting hematopoietic stem cells (HSCs) and down-
stream multipotent progenitor cells (MPPs) by whole-genome
sequencing (WGS) of clonally expanded primary cells from
human bone marrow. By analyzing clones derived from donors
of increasing age, we find that base substitutions gradually accu-
mulate in a linear fashion from birth throughout adult life, which is
driven by various endogenous mutational processes. One of
these processes is specific for HSPCs when compared to other
healthy organs and likely driven by mutagenic guanine analogs.
Although HSPCs are believed to extensively divide during
development (Bowie et al., 2006), the number of mutations at
birth is limited. Using base substitutions, we constructed a
developmental lineage tree revealing prenatal mutation rates,
a polyclonal architecture of the hematopoietic tissue, and a
multipotent but biased contribution of developmental lineages
to adult tissue. Together, our approach highlights features of
human hematopoiesis and its implications for hematopoietic
disease.
RESULTS
Cataloguing Somatic Mutations in Human HSCs and
MPPs
We have previously shown that clonal cultures of primary cells
can be used to characterize the dynamics of mutation accumu-
lation during human life in individual tissue-specific stem cells
(Blokzijl et al., 2016; Jager et al., 2018). To test whether a similar
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Figure 1. Determining Somatic Mutations in Hematopoietic Progenitors
(A) Schematic overview of experimental setup to catalog somatic mutations in single human blood progenitors. MSCs, mesenchymal stem cells; WGS, whole-
genome sequencing.
(B) Average number of base substitutions in HSCs and MPPs (extrapolated to the whole autosomal genome) of the donor A. Error bars indicate SD. Each data
point represents a single HSC or MPP clone. The p value indicates no statistical difference (NS) between the number of base substitutions in HSCs and MPPs
(two-sided t test).
(C) Relative contribution of the indicated mutation types to the base substitution spectra in HSCs andMPPs. Error bars indicate SD. Each data point represents a
single HSC or MPP clone.
(D) Average number of indels in HSCs andMPPs (extrapolated to thewhole autosomal genome) of the donor A. Error bars indicate SD. Each data point represents
a single HSC or MPP clone. The p values indicate no statistical difference (NS) between the number of indels in HSCs and MPPs (two-sided t test).multiparameter flow cytometry to sort phenotypically defined
long-term HSCs and MPPs obtained from human bone marrow
biopsies (Notta et al., 2016) and then clonally expanded them
to obtain sufficient DNA for WGS analysis (Figures 1A and S1).
We also performedWGS ofmesenchymal stem cells (MSCs) iso-
lated from the same bone marrow in order to exclude germline
variants. This procedure allowed us to catalog all the somatic
mutations present in the original stem cell, which accumulated
during the life of the cell. The majority of the somatic mutations
in these cultures displayed a variant allele frequency (VAF) clus-
tered around 0.5, which indicates that these mutations were
shared by all cells in the culture and therefore present in the orig-
inally expanded stem cell (Figure S2). A smaller VAF peak could
be observed around 0.2, which represents sub-clonal mutations
that accumulated after the first cell division in vitro and are not
shared by all cells in the cultures. These in vitro accumulated
mutations are discarded based on the low VAF (Figure S2). We
performedWGS onDNA from 18HSCs/MPPs derived from adult
marrow biopsies of 5 healthy donors, ranging from 26 to 63 years
of age (Table S1). In addition, we sequenced 4 clones isolatedfrom umbilical cord blood of 2 independent individuals to mea-
sure genome-wide somatic mutation load at birth. In total, we
identified 11,082 base substitutions and 553 small insertions
and deletions (indels). Independent validations using single-
molecule molecular inversion probes (smMIPs) of a subset
of the identified somatic mutations revealed an overall
confirmation rate of approximately 91% (Tables S2 and S4B).
We did not observe non-synonymous or truncating mutations
in cancer driver genes for hematological neoplasms (Ju et al.,
2017), excluding selective clonal outgrowth of cells in culture
(Table S3).
Long-term (LT)-HSCs and MPPs differ markedly in their ability
to engraft long term in transplantation recipients (Notta et al.,
2011; Oguro et al., 2013). Their proliferative histories and cell
cycle control machinery are also extensively documented to be
distinct (Foudi et al., 2009; Laurenti et al., 2015; Oguro et al.,
2013; Passegué et al., 2005; Wilson et al., 2008). Notably, we
found that the number and types of somatic mutations were
highly similar between HSCs and MPPs (Figures 1B–1D). Our
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Figure 2. Age-Associated Mutation Accumulation in Human Blood Progenitors
(A) Correlation of the number of base substitutions accumulated per genome with age of the independent donors we assessed. Each data point represents a
single clone. p value of the age effect in the linear mixed model is indicated above the plot (two-tailed t test). The sample size is 7 donors with a total of 22 clones
sequenced (9 HSCs, 9 MPPs, and 4 cord blood progenitors). Linear mixed model was performed on the clones from adult bone marrow (5 donors; 18 clones).
Dotted line indicates the extrapolation of this correlation to birth (age = 0). Subsequently, we confirmed this value at birth by performing WGS on umbilical cord
blood samples (n = 4 clones) of 2 independent donors.
(B) Annual base substitution rate estimated by the linear mixed model in (A). Error bars represent the 95% confidence interval of the slope estimate.
(C) Correlation of the number of indels with age of the donors. p value of the age effect in the linear mixed model is indicated above the plot (two-tailed t test).
Linear mixed model was performed on the clones from adult bone marrow. Dotted line indicates the extrapolation of this correlation to birth (age = 0).
(D) Relative contribution of the indicated mutation types to the base substitution spectra for each donor. The total number of base substitutions and assessed
clones per donor is indicated.
(E) Relative contribution of the indicated mutation types to the total number of indels for each donor. The total number of indels and assessed clones per donor is
indicated.and proliferation status do not affect genome-wide mutation
accumulation in these populations. Nonetheless, cells of the
same donor shared only a limited number of mutations (60 out
of 11,082 base substitutions; Table S1), indicating that muta-
genesis did occur independently during the lifetime of each
assessed cell. Hereafter, we will refer to the HSCs and
MPPs collectively as HSPCs, given their equivalent mutational
profile.
Age-Related Mutation Accumulation in Human Blood
Progenitors
A positive correlation (p < 0.05; t test linear mixed model) be-
tween the number of base substitutions and the age of the
donors was observed (Figure 2A), indicating a gradual accumu-
lation of this type of mutation during life. Base substitutions
accumulated with an annual rate of 14.2 mutations per year
(95% confidence intervals [CIs] are 6.1–22.4, respectively; Fig-
ure 2B), which remains very stable from birth throughout life.2310 Cell Reports 25, 2308–2316, November 27, 2018This observation indicates that the majority of mutations in adult
HSPCs accumulated during life, and only a limited number of
mutations (39.5; 95% CIs are 29.7–49.3, respectively; two-tailed
t test) are acquired prenatally. This is surprising, considering the
significant amount of cell proliferation that occurs during embry-
onic development and HSPC expansion in the fetal liver and the
relative quiescent status of LT-HSCs in the adult marrow (Bowie
et al., 2006). We detected a limited number of indels, which did
not seem to correlate with the age of the donor (Figure 2C). Mu-
tation spectra did not differ between donors (Figures 2D and 2E),
suggesting that underlying causative mutagenic processes are
equal among them.
Taken together, our results provide insight into the mutation
load in blood progenitors during life and at birth. Although accu-
mulation of indels is stem cell dependent, the linear age-related
accumulation of base substitutions and low inter- and intra-
donor variability argues for continuously acting mutational pro-
cesses during human life.
Processes Shaping the Tissue-Specific Mutational
Landscape in HSPCs
We next aimed to examine the processes that underlie age-
related mutation accumulation in HSPCs by analyzing mutation
spectra and underlying signatures (Alexandrov et al., 2013a).
We have previously reported that mutation spectra of human
stem cells can vary extremely between tissues (Blokzijl et al.,
2016). To compare the mutation spectra of HSPCs with stem
cells of these other human tissues, we performed a principal-
component analysis (PCA) using the contribution of the
6 different base substitution types in each cells while taking
the direct 50 and 30 nucleotide context into account (Figure 3B).
This PCA showed that stem cells cluster in a tissue-specific
manner (Figures 3A and 3B), underscoring the notion that the
underlying mutational processes can act in a tissue-specific
manner. To identify these processes, we performed mutational
signature analysis (Alexandrov et al., 2013b). The strongest fac-
tor in our PCA (PC1) separates cells with either high or low contri-
bution of signatures 1 or 5 (Figure S3), which are signatures that
were previously defined in a pan-cancer analysis (Alexandrov
et al., 2013b) and reported to act in a ‘‘clock-like’’ manner. Mu-
tation spectra in fast-cycling intestinal stem cells cluster toward
signature 1. This signature has been attributed to spontaneous
deamination of methylated cytosines into thymines (Alexandrov
et al., 2013b) and likely reflects a cell-cycle-dependent muta-
tional clock. Indeed, besides being the predominant mutational
signature in fast cycling intestinal stem cells (Blokzijl et al.,
2018), epithelial-derived cancers with a high cellular turnover
also show high signature 1 mutation rates (Alexandrov et al.,
2015). In contrast, mutation spectra in liver stem cells, thought
to be slow dividing in vivo, cluster toward signature 5, for which
the underlying process is still unknown (Alexandrov et al., 2015).
Mutation spectra in adult HSPCs cluster more toward signature
5 than 1 (PC1), in line with the idea that HSPCs become quies-
cent postnatally (Abkowitz et al., 2002; Bowie et al., 2006).
Indeed, signature 5 is the predominant contributor to the muta-
tion spectra in adult HSPCs, whereas the contribution of signa-
ture 1 to the mutation spectra in these cells is minor (Figure 3C).
Nonetheless, the number of mutations attributed to both signa-
tures accumulate in a linear fashion with age (Figure 3C), indi-
cating that also in these cells the underlying processes act in a
clock-like manner. Interestingly, the mutation spectrum of the
pooled umbilical cord blood clones clustered more toward
signature 1 (Figure 3A), likely reflecting the higher division rate
of HSPCs in utero (Bowie et al., 2006). Indeed, the relative contri-
bution of signature 1mutations in the umbilical cord blood clones
was 13-fold higher compared with the adult HSPCs (Figure 3C).
The presence of a third pattern, reflecting a recently defined
signature 32 (Inman et al., 2018), separates the mutation spectra
in HSPCs from stem cells of the other human tissues (PC2; Fig-
ures 3A and S3). This observation indicates that an additional
mutagenic process is active in the hematopoietic system, which
is reflected by signature 32. The number of mutations attributed
to signature 32 does not show a significant correlation with age,
suggesting it is not constantly active during life. Nevertheless, we
do observe presence of signature 32 in the umbilical cord blood
clones (Figure 3C), suggesting it likely represents an endoge-
nous mutagenic project. Signature 32 is characterized by C >T transitions with a preference for CpT or ApCp dinucleotides
(Inman et al., 2018). Although the etiology of signature 32 is
unknown, base substitutions specific for this signature were
associated with a transcriptional strand bias in the HSPCs (Fig-
ures 3D and S4), consistent with activity of transcription-coupled
repair (Pleasance et al., 2010). As C > T transitions are more pre-
sent on the transcribed compared with the untranscribed strand
(Figure 3D), our results argue that the lesion recognized by
transcription-coupled repair is likely a guanine adduct. Thus,
our data highlight unique specificmutational patterns and under-
lying mechanisms in HSPCs compared to other tissues.
Remarkably, the absolute contribution of all three signatures
to the base substitution load in normal HSPCs was similar as
those in a previously reported acute myeloid leukemia (AML)
dataset (Welch et al., 2012; Figure 3E; p = 0.97; chi-square
test; Figure S4B and S4C), indicating that the genesis of this
malignancy does not necessarily require enhanced mutagen-
esis. Nevertheless, comparing somatic mutation load in 72
known driver genes for hematological neoplasms (Ju et al.,
2017) revealed that the normal blood progenitors are depleted
for potential cancer driver mutations (0 mutations in 72 genes
out of 22 genomes; Table S3) compared to the AML samples
(28 mutations in 72 genes out of 24 genomes; p < 0.05; one-
sided binomial test; Welch et al., 2012). These potential driver
mutations included indels (11 out of 28) and base substitutions
(17 out of 28), of which 6 were C > T transitions (Welch et al.,
2012). These results argue that, instead of altered mutagenesis,
outgrowth of clones with stochastically acquired cancer-
initiating mutations as a consequence of mutational processes
active throughout life drives leukemogenesis (Alexandrov et al.,
2015).
Construction of a Developmental Lineage Tree
Somatic mutations acquired during embryogenesis provide
insight into developmental lineages and allow analysis of clonal
contributions to adult cell populations (Behjati et al., 2014; Ju
et al., 2017). Using the base substitutions identified in 10 WGS
HSPCs from donor A, we determined genetic relatedness be-
tween these cells by assessing mutations that are shared be-
tween the different cells. In this analysis, somatic mutations
that are shared between HSPCs of the same donor are indicative
for a common ancestral cell. The more mutations two clones
share, the later during development they separated. Using these
sharedmutations, we constructed a hypothetical developmental
lineage tree (Figure 4A). Of note, the HSPCs shared very few
mutations. As we obtain the somatic mutations by comparing
to a donor-matchedMSC sample, our analysis may be excluding
base substitutions that were acquired during early embryonic
development and also with low frequency present in this paired
MSC sample. Therefore, we included mutations with sub-clonal
evidence (variant allele frequency < 0.3) in the paired MSC
control sample from this donor (STAR Methods). To evaluate
the ability of our reconstructed map to explain lineage relation-
ships in the bone marrow, we genotyped each base substitution
defining a branch in 125 additional HSCs and MPP clones from
the same donor (Table S4A). By genotyping these mutations,
we could only attribute 81 out of 125 clones to the projected
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Figure 3. Signatures of Mutational Processes in HSPCs
(A) Principal-component analysis of 96-base substitution spectra. Spectra of single base substitutions sequenced clones (colored dots, 16 colon, 13 small
intestine, 10 liver, 18 HSPCs, and 4 cord blood clones) and 96 profiles of signatures. Mutations for all four umbilical-cord-blood-derived samples were pooled
together, as mutation load was low in these samples. Directions of signature contributions between samples are indicated on the x and y axis; see Figure S3.
(B) Total 96 mutational profiles for all mutations in the HSPC clones.
(C) Absolute contribution of each mutational signature type (extrapolated to the whole autosomal genome) plotted against the age of the donors. The observed
absolute contributions of the signatures in the umbilical cord blood are plotted as triangles, and the numbers are indicated in the plot marked with CB. The
p values of the age effects per tissue are shown (linear mixed model; two-tailed t test, excluding the cord blood data) with extrapolations of signature
accumulation to the birth drawn in dotted lines.
(D) Transcriptional strand bias profile for all C > T transitions in HSPCs (pooled); *p < 0.05; two-sided Poisson test.
(E) Mean base substitution load per year per 10-MB genome of the indicated mutational signature types for the HSPC clones (n = 18) and the AML samples
(n = 24). The total number of base substitutions and assessed samples per category is indicated. Error bars indicate SD. Each data point represents a single HSPC
or AML sample.incomplete and we missed developmental branches. We
reasoned that, by performing WGS in a bulk granulocyte sample
of this donor, we would identify the somatic mutations to com-
plete the tree. To this end, we aimed to find mutations with
sub-clonal evidence in both the bulk granulocyte sample and2312 Cell Reports 25, 2308–2316, November 27, 2018the control MSC sample but that were absent in any of the
WGS clones. This approach allowed us to identify two additional
somatic mutations that defined an additional branch of the tree
to which the remaining 44 progenitor clones could be attributed


























































































C Figure 4. Reconstruction of theDevelopment
Lineage Tree and Branch-Specific Contribu-
tions to Different Blood Lineages
(A) Phylogenetic tree indicating the relatedness of
the whole-genome sequenced clones. The different
branches, which are defined by individual somatic
base substitutions, are indicated with letters a–m. In
the gray panel, the presence or absence of those
base substitutions (y axes) in both the whole-
genome sequenced clones and amplicon-based
sequenced clones (x axes) are for HSCs (black) and
MPPs (gray). The ɑ branch highlighted with red-
dashed box showed asymmetrical contribution to
HSCs and MPPs with a statistical significance (p <
0.05; permutation test).
(B) As a continuation of the phylogenetic tree, the
number of their unique mutations in theWGS clones
(black for HSCs; gray for MPPs) is shown by the
length of their branches. The red horizontal line in-
dicates the time of birth estimated based on the
average number of base substitutions in the umbil-
ical cord blood cells with the 95% confidence
interval as gray box.
(C) Dendrogram depicting the correlations between
the mature populations based on the hierarchical
clustering of variant allele frequencies (VAFs) of the
somatic mutations a–m.back to two cells likely arising in the first divisions of the human
embryo. The number of mutations defining each branch indi-
cated a rate of 1 base substitution per embryonic cell doubling,
which is in line with previous reports (Ju et al., 2017; Lee-Six
et al., 2018). If we assume that cell proliferation rate is stable
during development, we estimated that, at birth, HSPCs have
undergone approximately 40 divisions, based on the average
number of base substitutions in the umbilical cord blood sam-
ples (Figure 4B).
Unequal Contribution of Embryonic Lineages to the
Adult Hematopoietic Tissue
The reconstructed phylogeny revealed a pattern of asymmetric
contribution of developmental branches to the adult hematopoi-
etic stem cell and progenitor compartment, in line with previousCell Reporobservations in other tissues (Behjati et al.,
2014; Ju et al., 2017). For instance, 65%
of HSPCs are derived from branch a
compared with branch b (p < 0.05; one-
sided binomial test). Notably, this biased
contribution was not as prevalent in the
MSCs (Figure 4A), suggesting that such
hematopoietic-specific asymmetry may
have arisen later in development. Interest-
ingly, we also observed biased contribu-
tion of some tree branches to the pools of
HSCs and MPPs. For instance, branch
a (Figure 4A) is significantly enriched for
HSC clones (21 HSCs out of 37 clones;
p < 0.05; permutation test). This finding
might be suggestive of a non-overlappingdevelopmental origin of some HSCs and MPPs, although we
cannot rule out stochastic clonal amplification of these subsets
postnatally.
Recent data have suggested that unilineage priming may
occur in mice and humans at the level of HSC (Carrelha et al.,
2018; Rodriguez-Fraticelli et al., 2018), and barcoding in the
mouse embryo has suggested the presence of lineage-
restricted HSCs (Pei et al., 2017). We wanted to assess the
extent of developmental potency of the human developmental
clones identified. To determine the contribution of each branch
to mature hematopoietic tissue, we assayed for the presence
of branch-specific base substitutions in sorted granulocytes,
erythroblasts, pre-B cells, and megakaryocytes from the
same bone marrow biopsy. Our data indicated that each devel-
opmental hematopoietic branch displayed some contributionts 25, 2308–2316, November 27, 2018 2313
to every single one of the assessed mature cell populations
(Figure 4A). Of particular interest are base substitutions
defining the last branching generation of the tree (branches
l, m, and j), which are absent in MSCs, suggesting that these
mutations arose during or after hematopoietic specification
(considering that some MSCs are also mesodermally derived).
Notably, these base substitutions also showed presence in
most mature cell populations, underlining the multipotent na-
ture of such developmental hematopoietic clones (Figure 4A;
Notta et al., 2016). Hierarchical clustering of the different blood
lineages by the contribution of each developmental branch
to these populations revealed early branching of MSCs from
mature blood lineages. Of these blood lineages, the megakar-
yocyte branch splits off more early, suggesting lineage differ-
ences between megakaryocytes and the other blood popula-
tions (Figure 4C), which is in line with recent observations in
mice (Haas et al., 2015; Rodriguez-Fraticelli et al., 2018; Yama-
moto et al., 2013).
DISCUSSION
This study presents the survey of somatic mutation accumula-
tion in normal HSPCs during human life and provides insight
into the development and age-relatedmutagenesis of this tissue.
We show that HSPCs after birth accumulate mutations at a
stable rate of approximately 14 base substitutions per year.
This rate is in the same range as previously reported for human
neurons of the prefrontal cortex (Lodato et al., 2018) and approx-
imately two-fold lower compared with stem cells of human
colon, small intestine, liver, and neurons of the dentate gyrus
(Blokzijl et al., 2016; Lodato et al., 2018). As human HSCs are
thought to divide every 40 weeks (Catlin et al., 2011), our results
suggest that they accumulate approximately 11 mutations per
division. In contrast, our phylogenetic analysis shows that each
of the developmental lineage branches, reflecting embryonic
cell-doubling events (Ju et al., 2017), is defined by 1 mutation,
suggesting that the per-division mutation rate is lower during
development. Indeed, our data indicate that, at birth, HSPCs
accumulate about 40 mutations, and these cells undergo many
rounds of cell division during development (Bowie et al., 2006).
In addition, we determined that the number and types of somatic
mutations were highly similar between LT-HSCs and MPPs,
even though these cell types are documented to differ exten-
sively in their proliferative responses, cell cycle control machin-
ery, and ability to produce long-term grafts in transplantation
recipients (Foudi et al., 2009; Laurenti et al., 2015; Oguro et al.,
2013; Wilson et al., 2008). Together, these observations suggest
that differences in potency and self-renewal capacity might not
be the most important determinant of somatic mutation load. It
has been estimated that humans have about 50,000–200,000
active HSCs per person (Lee-Six et al., 2018), which would indi-
cate that, in a lifetime of 80 years, approximately 60–240 million
bases are mutated in the complete active stem cell pool. In line
with this, our data suggest that no enhanced mutagenesis is
needed to explain somatic base substitution load in AML. Muta-
tional signature analysis indicated that the majority of base
substitutions are generated by two processes that are age
dependent and constantly active during life. One of these pro-2314 Cell Reports 25, 2308–2316, November 27, 2018cesses, reflected by signature 1, is thought to be driven by spon-
taneous deamination of methylated cytosines into thymines
(Alexandrov et al., 2013b). As this signature has been found to
act in a clock-like manner in cancers derived from normal
epithelia with a high turnover (Alexandrov et al., 2015) as well
as in fast cycling small intestinal and colon stem cells (Blokzijl
et al., 2016), this signature may represent a cycle-dependent
mutational clock. In line with this, the contribution of signature
1 in adult HSPCs, which are mostly quiescent after birth (Catlin
et al., 2011), is minor, whereas at birth, the mutation spectra of
HSPCs resemble fast-cycling human stem cells, potentially re-
flecting the massive proliferation of HSPCs in utero (Bowie
et al., 2006). In contrast, the most predominant contributor of
mutagenesis in adult HSPCs is signature 5, which can also act
in a clock-like manner in cancers (Alexandrov et al., 2015) and
in slowly cycling liver stem cells (Blokzijl et al., 2016) and likely
reflects a cell-cycle-independent mutational clock. Presence of
a third novel signature (signature 32) in the HSPCs defines the
tissue specificity of the mutation spectra observed in the he-
matopoietic cells. This signature has been associated with
azathioprine therapy (Inman et al., 2018), which can cause se-
vere hematological toxicities (Karran and Attard, 2008). Of
note, the transcriptional strand bias effect in the HSPCs can be
only partially explained by the reported bias of signature 32 (In-
man et al., 2018), suggesting that the underlying transcription
blocking lesion might be slightly different from guanine metabo-
lites that result from azathioprine treatment. To our best knowl-
edge, none of the donors have been treated with azathioprine,
arguing that the presence of this signature in healthy donors
might reflect mutagenic action of endogenously generated
guanine metabolites. Indeed, signature analysis of the pooled
umbilical cord blood samples indicated that signature 32 muta-
tions are already present at birth and thus acquired in utero.
Finally, by using base substitutions, we were able to trace the
developmental history of the hematopoietic stem and progenitor
compartment in the bonemarrow, demonstrating that asymmet-
rical contributions shape hematopoietic system ontogeny. Our
study also provides support for the functional multipotent nature
of early developmental hematopoietic clones. Thus, somatic
mutations in blood progenitors provide a means to study lineage
relationships of native human hematopoiesis.STAR+METHODS
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ruben
van Boxtel (R.vanBoxtel@prinsesmaximacentrum.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human bone marrow biopsies and umbilical cord blood
Sample B (26-year-old donor, male, white) was extracted at Boston Children’s Hospital, whereas samples A (33-year-old, male,
white), C (55-year-old, female, hispanic), D (63-year-old, male, white), and E (41-year old, female, African American) were obtained
from AllCells (Table S1). 10-20mL of whole bonemarrow aspirate were drawn into a 60cc syringe containing heparin (80 U/mL of BM)
from a unique puncture in the posterior iliac crest. All the donors were healthy and did not show previous conditions. Patient’s
informed consents were obtained by Boston Children’s Hospital and AllCells, respectively. Umbilical cord blood samples CB-1
(0-year old, female, ethnicity unknown) and CB-2 (0-year old, male, ethnicity unknown) was obtained at the University Medical Center
Utrecht and theWilhelmina Children’s Hospital. Informed consent was obtained and this study was approved by the ethical commit-
tee of University Medical Center Utrecht. No differences related with sex or gender of the samples were detected in this study.
METHOD DETAILS
FACS
Erythrocytes were removed from the bone marrow samples using red blood cell lysis buffer. CD34-enrichment was performed using
magnetic-assisted cell sorting with anti-CD34 magnetic beads (Miltenyi Biotech, 130-046-703). Different cell populations were pu-
rified through using FACSAria (Becton Dickinson) and MoFlo XDP (Beckman Coulter) equipment. The following combinations of cell
surface markers were used to define cell populations(Notta et al., 2016). HSC: CD34+CD38-CD45RA-CD90+CD49f+; MPP:
CD34+CD38-CD45RA-CD90-CD49f-; Granulocytes: CD66b+CD11b+CD19-CD10-CD235a-CD41-CD42b-; Erythroblasts:
CD235a+CD66b-CD11b-CD19-CD10-CD41-CD42b-; pre-B cells: CD19+CD10+CD66b-CD11b-CD235a-CD41-CD42b-; Megakar-
yocyte progenitors: CD41+CD42b+CD66b-CD11b-CD19-CD10-CD235a-. Representative examples of sorted populations are
shown in the Figure S1B. Flow cytometry data was analyzed using FlowJo software (Tree Star). Polyclonal mesenchymal stem cells
(MSCs) cultures were established from a fraction of whole bone marrow samples after red blood cell lysis, cells were plated in tissue
culture treated dishes in DMEM-F12 medium (GIBCO), supplemented with 10% FBS. MSCs were kept in culture for a week and me-
dium was replaced each day to remove non-adherent cells. Umbilical cord blood mononuclear cells were isolated by density centri-
fugation over Lymphoprep (Stem Cell Technologies). Umbilical cord blood progenitors were sorted on the following cell markers:
(CD34+, CD38-, CD45RA-, CD11c-, CD16-, Lin(CD3/14/19/20/56)-) and clonal cultures were established in the same manner as
the HSPCs (below).
FACS antibodies
All antibodies were used at 1:100 dilution unless noted. Antibodies used for bone marrow isolation of HSPC andmature populations:
CD34-PB (Biolegend, clone 581, 343512), Thy1/CD90-PE (Biolegend, clone 5E10, 328110), CD45RA-FITC (Biolegend, clone HI100,
304106), CD49f-APC-Cy7 (Biolegend, clone GoH3, 313628), CD38-PE-Cy7 (eBioscience, clone HB7, 25-0388-42), CD66b-FITC
(Biolegend, clone G10F5, 305103), CD11b-APC-Cy7 (Biolegend, clone ICRF44, 301341), CD19-PB (Biolegend, clone HIB19,
302223), CD42b-PE (Biolegend, clone HIP1, 303905), CD10-A700 (eBioscience, clone eBioCB-CALLA, 56-0106-41), CD41-PE-
Cy7 (eBioscience, Clone HIP8 25-0419-41), CD235a-APC (eBioscience, clone HIR2, 17-9987-41). Antibodies used for umbilical
cord blood MPP isolation: CD34-BV-421 (Biolegend, Clone 561, 343609, 1:20), CD38-PE (Biolegend, Clone HIT2, 303505, 1:50),
CD45RA-PerCP/Cy5.5(Biolegend, Clone HI100, 304121, 1:20), Lineage(CD3/CD14/CD19/CD20/CD56)-FITC(Biolegend, Clones
UCHT1, HCD14, HIB19, HCD56, 348701, 1:20), CD16-FITC (Biolegend, Clone 3G8, 302005), CD11c-FITC (Biolegend, Clone 3.9,
301603, 1:20)
Establishment of clonal HSC/MPP cultures
HSCs and MPPs were first sorted into a collection tube and a second index sort was performed to seed single-cells into round-bot-
tom 384-well plates. Cell were cultured in StemSpan SFEMmedium supplemented with SCF (100 ng/mL), FLT3-L (100 ng/mL), TPO
(50 ng/mL), IL-6 (20 ng/mL) and IL-3 (10 ng/mL) at 37C, 5%CO2 for 3-4 weeks before collection.
Whole-Genome Sequencing and Read Alignment
DNA libraries for Illumina sequencing were generated by using standard protocols (Illumina) from 20 - 50 ng of genomic DNA isolated
from the clonally expanded blood progenitors using DNeasy Blood & Tissue Kit (QIAGEN) according to manufacturer’s instructions.
All samples were sequenced (2 3 150 bp) by using Illumina HiSeq X Ten sequencers to 30x base coverage. Sequence reads were
mapped against human reference genomeGRCh37 by using Burrows-Wheeler Aligner v0.5.9 mapping tool(Li and Durbin, 2010) with
settings ‘bwamem -c 100 -M’. Sequence readsweremarked for duplicates by using Sambamba v0.4.732 and realigned per donor bye2 Cell Reports 25, 2308–2316.e1–e4, November 27, 2018
using Genome Analysis Toolkit (GATK) IndelRealigner v2.7.2, and sequence read quality scores were recalibrated with GATK Base-
Recalibrator v2.7.2. Full pipeline description and settings also available at: https://github.com/UMCUGenetics/IAP.
Mutation calling and filtering
Raw variants were multisample-called by using the GATK HaplotypeCaller v3.4-46 (DePristo et al., 2011) and GATK-Queue v3.4-46
with default settings and additional option ‘EMIT_ALL_CONFIDENT_SITES’. The quality of variant and reference positions was eval-
uated by using GATK VariantFiltration v3.4-46 with options ‘-snpFilterName LowQualityDepth -snpFilterExpression ‘‘QD < 2.0’’
-snpFilterName MappingQuality -snpFilterExpression ‘‘MQ < 40.0’’ -snpFilterName StrandBias -snpFilterExpression ‘‘FS > 60.0’’
-snpFilterName HaplotypeScoreHigh -snpFilterExpression ‘‘HaplotypeScore > 13.0’’ -snpFilterName MQRankSumLow -snpFilter-
Expression ‘‘MQRankSum < 12.5’’ -snpFilterName ReadPosRankSumLow -snpFilterExpression ‘‘ReadPosRankSum < 8.0’’
-cluster 3 -window 35’. To obtain high-quality somatic mutation catalogs, we applied postprocessing filters as described(Blokzijl
et al., 2016). Briefly, we considered variants at autosomal chromosomes without any evidence from a paired control sample
(MSCs isolated from the same bone marrow); passed by VariantFiltration with a GATK phred-scaled quality score R 100 for base
substitutions and R 250 for indels; a base coverage of at least 20X in the clonal and paired control sample; no overlap with single
nucleotide polymorphisms (SNPs) in the Single Nucleotide Polymorphism Database v137.b3730; and absence of the variant in a
panel of unmatched normal human genomes (BED-file available upon request). We additionally filtered base substitutions with a
GATK genotype score (GQ) lower than 99 or 10 in clonal or paired control sample, respectively. For indels, we filtered variants
with a GQ score lower than 99 in both clonal and paired control sample and filtered indels that were present within 100 bp of a called
variant in the control sample. In addition for both SNVs and INDELs, we only considered variants with amapping quality (MQ) score of
60 and with a variant allele frequency of 0.3 or higher in the clones to exclude in vitro accumulated mutations (Blokzijl et al., 2016;
Jager et al., 2018).
Principal component analysis
The occurrences of all 96-trinucleotide changes were counted for each HPSC and averaged per donor. In this analysis, we included,
besides the blood progenitors, genome-wide mutation catalogs of individual adult stem cells of colon, small intestine and liver (Blok-
zijl et al., 2016). As for the umbilical cord blood samples mutational load was low, possibly affecting the outcome, all four umbilical
cord blood-derived samples were pooled together. Principal component analysis was performed using the base R function prcomp.
Mutational profile and signature analysis
To identify most prominent signatures, which gives the largest separation to the clones in a plane in a principal component analysis,
we extracted principal components 1 (PC1) and 2 (PC2), and separated positive and negative signals of the components. Using a in-
house developed R package (MutationalPatterns) (Blokzijl et al., 2018), the patterns of the extracted components were compared to
the COSMIC SigProfiler signatures (https://www.synapse.org/#!Synapse:syn11967914) and from their cosine similarities, Signature
1, 5 and 32 were selected. These three signatures were subsequently refitted to the adult HSPC data and the pooled umbilical cord
blood mutational profiles. To determine contribution of signatures to the mutation load in AML, we obtained somatic mutation cat-
alogs which were identified in the nonrepetitive portion of the genome (50% of the entire genome(Mardis et al., 2009)) of 24 AML
samples(Welch et al., 2012). We determined the COSMIC SigProfiler signature contribution similarly as performed on HSPC data. To
determine the transcriptional strand contribution and bias, we selected all point mutations that fall within gene bodies and checked
whether the mutated C or T was located on the transcribed or non-transcribed strand.
Transcriptional strand bias analyses
We used a in house developed R package (MutationalPatterns)(Blokzijl et al., 2018) to determine transcriptional strand bias as de-
scribed(Blokzijl et al., 2016). Transcriptional strand bias is calculated with the transcriptional single base substitution signatures ob-
tained from the COSMIC Transcriptional Strand Signatures (https://www.synapse.org/#!Synapse:syn11967914).
Amplicon analysis of SNVs
DNA from the HSPC clones was extracted using QIAGEN DNeasy Blood and tissue kit (QIAGEN). A first amplicon-specific PCR was
performed (primer sequences available upon request) using TruSeq Illumina adapters, then a second indexing PCR was performed.
The DNA library was sequenced using the MiSeq reagent kit v2 500 cycles. Raw sequencing data was aligned against the human
reference genome (hg19) using BWA-mem(Li and Durbin, 2010). The alignment data was compressed, sorted and indexed using
SAMTOOLS(Li et al., 2009) and the per position sequencing information was extracted in pileup format requiring a minimum
sequencing and mapping phred scores of 25 and 15 respectively. Finally, an in-house written perl script was used to calculate
the read counts supporting both reference and variant alleles for each position of interest as well as to calculate variant allele
frequencies.
smMIP analysis of SNVs
Clone-specific smMIPs were designed as described(Hiatt et al., 2013; Yu et al., 2018), (Table S4B). The genomic regions of interest
were captured using 10ng for the indicated clones and 100 ng of genomic DNA for the matching granulocyte samples. UMICell Reports 25, 2308–2316.e1–e4, November 27, 2018 e3
sequences were trimmed from sequenced smMIP reads and mapped to the human reference genome (hg19) using BWA-mem al-
gorithm with -M option(Li and Durbin, 2010). For each UMI with at least 5 reads, the sequenced nucleotide at the mutation position
were extracted for every read. When 70% or more of the reads with the same UMI had the same nucleotide, then the UMI was
counted as valid as described(Yu et al., 2018)Mutation positionswith less than 20 valid UMI’s were filtered out, and the rest mutations
with higher than 0 VAF were counted as validated (Table S2). For bulk granulocyte data, the non-validated positions and positions
with less than 20 valid UMI’s were excluded.
Construction of developmental lineage tree
We first constructed a developmental lineage tree by cataloguing somatic base substitutions, which were shared between the 10
whole-genome sequenced clones of donor A. To obtain base substitutions that were acquired during early embryonic development,
we included mutations with sub-clonal (VAF < 0.3) evidence in the paired MSC control sample that were either clonally present or
completely absent in the 10 clones. All of these shared base substitutions were manually inspected and false positive calls were
excluded. To complete the tree, we whole-genome sequenced the bulk granulocyte samples and search for base substitutions
that were sub-clonally present in the granulocytes and the paired MSC control sample without any evidence in the 10 whole-genome
sequenced clones. We also considered mutations observed in clones and with sub-clonal evidence in the granulocytes. These mu-
tations were also manually inspected and false positive calls excluded. For all of these early embryonic base substitutions primers
were designed for amplicon-base re-sequencing in the mature populations and HSC and MPP clones as described above (Table
S4A). In total, we sequenced 140 clones, 62 HSCs and 78MPPs, fromwhich we excluded 9HSC and 6MPP clones from the analysis,
because they had less than 10x coverage at any of the selected substitutions or showed evidence for multiple base substitutions and
could therefore not be assigned to a branch. A binary mutation table was created to summarize the shared base substitutions. To
construct a heatmap with a lineage tree, lineage distances were calculated using binary method, clones were hierarchically clustered
using average method and plotted using gplots package in R.
QUANTIFICATION AND STATISTICAL ANALYSIS
Sample and mutation numbers are indicated in the figures. Data are shown as mean ± standard deviation. For the slope estimation,
the linear mixed model was used to take donor dependency into account and the p values are indicated in the figures. To assess
statistical significance of mutation numbers between two groups, a two-sided t test was used after testing normality of data distri-
bution using the Shapiro–Wilk test and equality of variances. To assess statistical significance of mutation spectra between two
groups, a chi-square test was used. To assess statistical significance of enrichment or depletion of mutations in different genomic
regions, the number of progenitor clones in different branches, or depletion of potential cancer-driver mutations in the normal blood
progenitors, a one-sided binomial test was used. To assess statistical significance between distribution of HSCs and MPPs in
different branches a permutation test was used.
DATA AND SOFTWARE AVAILABILITY
Code Availability
Mutation calling and filtering pipelines are available at https://github.com/UMCUGenetics/IAP, https://github.com/UMCUGenetics/
SNVFI and https://github.com/ToolsVanBox/INDELFI, smMIP analysis script is available at https://github.com/ToolsVanBox/
smMIPfil. The other scripts are available on request.
Data availability
The accession number for the whole-genome sequence data reported in this paper is EGA: EGAS00001003068.e4 Cell Reports 25, 2308–2316.e1–e4, November 27, 2018
